Briefing
Resected pancreatic cancer: landmark ctDNA positivity was associated with earlier recurrence
An ASCO 2025 interim analysis of 112 patients with resected stage I to III pancreatic adenocarcinoma reported that landmark postoperative ctDNA positivity predicted recurrence (HR 2.39; 95% CI 1.14 to 5.01), and longitudinal positivity was associated with shorter disease-free survival (HR 3.13).